Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA cleared Luminopia, a virtual reality-based therapeutic for amblyopia, for use in children aged 8 to 12 years old, adding to its existing approval in children aged 4 to 7 years old, according to a press release.
It represents the first FDA clearance in more than 20 years for amblyopia in this age range, which has traditionally been treated with eye patching and atropine drops, according to Luminopia.
“Luminopia is the only treatment for amblyopia (Read more...)